IEX — IDEX Corporation

IDEX Corporation Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Organic Sales Growth: 5% year-over-year, with notable strength in the Health & Science Technologies (HST) segment (11% growth).
• Adjusted EBITDA Margin: 26%, reflecting a 50 basis point year-over-year expansion.
• Orders Growth: 10% organic growth in orders, led by HST (17% growth) and Fluid & Metering Technologies (FMT) (9% growth). Fire & Safety (FSDP) orders declined 4%.
• Free Cash Flow: $86 million, down $5 million year-over-year due to higher working capital investments.
• Share Repurchases: $76 million in Q1, with plans to maintain this pace throughout 2026.
• Adjusted EPS: Significantly higher than guidance, with an updated full-year guidance of $8.35 to $8.55.

2. Strategic Updates and Business Highlights

• IDEX is focusing on its 8020 strategy to drive growth, emphasizing high-value applications in sectors like data centers, semiconductors, and space and defense.
• The HST segment is experiencing strong demand due to its exposure to high-value applications, with a robust backlog expected to support growth into 2027.
• The company is actively pursuing tuck-in acquisitions while maintaining a strong balance sheet for flexibility.
• IDEX is leveraging its existing technologies and relationships to expand in critical markets, particularly in space and defense.

3. Forward Guidance and Outlook

• 2026 Guidance: Organic growth is now expected in the 3% to 4% range, up from the previous 1% to 2%. HST is expected to grow at high single-digit rates, while FMT and FSDP are projected to be flat.
• Adjusted EBITDA Margin: Expected to remain in the 26.5% to 27% range for the year.
• Q2 2026 Expectations: Anticipated organic growth of 3% to 4%, with adjusted EBITDA margin in the same range as the full year.

4. Bad News, Challenges, or Points of Concern

• FSDP Segment: Experienced a decline in orders and sales, attributed to tough comparisons and project volume reductions in North America and Asia.
• Life Sciences Market: Facing pressures from NIH funding and market dynamics in China, leading to low single-digit growth.
• Geopolitical Uncertainty: Continues to create a cautious outlook for the short-cycle industrial businesses, impacting visibility and order rates.
• Mixed Performance: While HST is strong, FMT and FSDP show signs of weakness, indicating potential risks in overall growth sustainability.

5. Notable Q&A Insights

• Management indicated that the second quarter's expected deceleration in growth is primarily due to macroeconomic uncertainties, particularly in the FMT segment.
• There are ongoing efforts to improve margins in the HST segment, particularly through the integration of recently acquired businesses.
• The company remains committed to its share repurchase program while actively seeking M&A opportunities, particularly in bolt-on acquisitions.
• Management expressed confidence in the long-term growth potential of the HST segment, especially in light of increasing demand in space and defense markets.
• The conversation highlighted the importance of maintaining flexibility in pricing strategies to counteract inflationary pressures and tariffs.

Overall, IDEX demonstrated a strong start to 2026, with robust growth in specific segments, although challenges remain in others, particularly in the FSDP and life sciences markets. The company is optimistic about its strategic direction and growth initiatives.